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OBJECTIVES: The Helicobacter pylori (H. pylori) “test-and-
treat” strategy in uninvestigated dyspepsia is an effective
alternative to prompt endoscopy. Our aims were to deter-
mine whether the combination of an educational session and
availability of office-basedH. pylori testing (test-and-treat
intervention [TTI]) increases use of the test-and-treat strat-
egy by primary care practitioners and whether it improves
patient outcomes.
METHODS: We conducted a 1-yr prospective trial of patients
with suspected peptic ulcer disease in six primary care
centers, three with TTI and three designated as usual care
controls (UCC).
RESULTS: H. pylori testing was performed in 81% of 54 TTI
patients and in 49% of 39 UCC patients (p  0.004). TTI
and UCC patients had similar gastroenterology referral rates
(24% vs 33%,p  0.33), endoscopy or upper GI radiogra-
phy rates (30%vs 31%,p  0.91), and primary care visits
per patient (3.1 2.8 vs3.1  2.6,p  0.92). TTI patients
were less likely than UCC patients to receive repeated
antisecretory medication prescriptions (35%vs 66%, p 
0.003). Symptomatic status at 1 yr and satisfaction with
medical care did not differ between groups. Median (and
interquartile range) annualized disease-related expenditures
per patient were $454 ($162–932) for TTI and $576 ($327–
1435) for UCC patients (p  0.17).
CONCLUSIONS: The combination of an educational session
and availability of office-basedH. pylori testing may in-
crease acceptance of the test-and-treat strategy by primary
care providers. It remains to be determined whether in-
creased use of the test-and-treat strategy yields significant
improvements in clinical and economic outcomes compared
to usual care. (Am J Gastroenterol 2002;97:3007–3014.
© 2002 by Am. Coll. of Gastroenterology)
INTRODUCTION
Dyspepsia, characterized by upper abdominal pain or dis-
comfort with or without associated symptoms, is experi-
enced by approximately 25% of the population annually and
accounts for up to 5% of primary care visits (1). Numerous
practice guidelines advocate noninvasive testing forHeli-
cobacter pylori (H. pylori) in patients with uncomplicated
dyspepsia (2–7). Observational studies first suggested that
screening forH. pylori might decrease endoscopic workload
(8, 9), and cost-effectiveness analyses identified the “test-
and-treat” strategy as a reasonable alternative to prompt
endoscopy (10, 11). Recently, European randomized trials
have provided evidence that the test-and-treat strategy
yields similar clinical outcomes and lower endoscopic rates
than a strategy of prompt endoscopy (12, 13).
The impact of practice guidelines on patient care ulti-
mately depends on the implementation of such guidelines by
clinicians (14). Numerous strategies have been used to pro-
mote integration of clinical research findings into clinical
practice, with passive dissemination of information gener-
ally proving ineffective (15). In contrast, educational out-
reach visits to clinicians and combinations of two or more
interventions may increase the likelihood of affecting prac-
tice patterns (15).
We hypothesized that educational sessions onH. pylori
and the test-and-treat strategy provided by gastroenterology
subspecialists, in combination with establishing office-
basedH. pylori testing, would increase use of the test-and-
treat strategy by primary care providers caring for patients
with suspected peptic ulcer disease when compared to “usu-
al care” after passive dissemination of information. To test
this hypothesis, we designed a study comparing practice
patterns and patient outcomes for patients with suspected
peptic ulcer disease at three primary care centers that re-
ceived the combined intervention and at three centers ex-
posed only to passive dissemination of a practice guideline.
Our primary aim was to determine whether the combined
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intervention increased use of the test-and-treat strategy. Our
secondary aim was to explore whether greater acceptance of
the test-and-treat strategy improved clinical outcomes and
decreased disease-related expenditures compared to usual
care outside the constraints of a strict protocol to reflect
community practice in the United States.
MATERIALS AND METHODS
Practice Guideline
In 1996, an evidence-based practice guideline on suspected
peptic ulcer disease was disseminated by campus mail to all
University of Michigan Health Care System primary care
providers. The guideline has been described in depth pre-
viously (16). The guideline endorsed a test-and-treat strat-
egy in patients with symptoms suggestive of uncomplicated
peptic ulcer. Prompt referral to a specialist was recom-
mended for patients with symptoms or signs suggestive of
complicated ulcer or malignancy, and for individuals with
persistent or recurrent symptoms after H. pylori testing and
initial treatment. Early referral was recommended for pa-
tients aged 50 yr. For patients taking nonsteroidal anti-
inflammatory drugs, drug discontinuation was recom-
mended, followed by the test-and-treat strategy for
persistent symptoms. Proton pump inhibitor–based triple
therapy was listed as the preferred H. pylori eradication
therapy, but several regimens with costs and eradication
rates were presented. For patients who tested negative for H.
pylori, no specific therapy was recommended, and manage-
ment was left to the discretion of the treating clinician.
General Study Design
The Institutional Review Board of the University of Mich-
igan approved the study and all patients signed an informed
consent document before enrollment. Within the University
of Michigan Health Care System, six primary care centers in
the community (all within 20 miles of the University Hos-
pital in Ann Arbor) were included in the study. Three
centers were randomized to receive no intervention, and
were designated as usual care controls (UCC). Two centers
were randomized and one center that was already initiating
on-site H. pylori serological testing was assigned to receive
a test-and-treat intervention (TTI), described below.
Participating providers did not practice at different sites,
minimizing the potential for contamination of the UCC sites
by the educational sessions provided at the TTI sites. In
addition, providers were aware that this study involved
patients with suspected peptic ulcer disease, but they were
not aware of the specific hypotheses, the details of the study
design (including the difference between UCC and TTI
sites), or the outcomes of interest. The practice patterns of
general medicine providers and the outcomes of patients
with suspected peptic ulcer disease were compared between
UCC and TTI sites, as described below.
Test-and-Treat Intervention
At the three TTI sites, 1-h educational sessions were pro-
vided to all general medicine practitioners. These interactive
sessions were led by two of the authors (J.S. and U.L.). The
sessions focused on the etiology and clinical presentation of
peptic ulcer disease, the role of H. pylori in peptic ulcer
disease and other causes of dyspepsia, the test-and-treat
strategy, and the use of on-site H. pylori serological testing.
In addition, the practice guideline on suspected peptic ulcer
disease was reviewed. These educational sessions were
combined with the establishment of office-based, whole
blood H. pylori serological testing at each TTI center (Flex-
Pack HP, Abbott Diagnostics, Abbott Park, IL). In a trial
including our institution, FlexPack HP was found to have a
sensitivity of 76% and a specificity of 79% (17), results
similar to those of another recently published study (18).
Thus, clinicians were able to test a patient for H. pylori
during the visit in which they suspected peptic ulcer disease.
Patient Population With Suspected Peptic Ulcer Disease
From November 1996, through April 1998, general medi-
cine practitioners in all six centers were invited to identify
patients with suspected peptic ulcer disease. Although the
practice guideline emphasized that symptoms are poor pre-
dictors of peptic ulceration, the following were identified as
possible symptoms of peptic ulcer disease: gnawing or burn-
ing epigastric pain, pain relieved with food or antacids, and
pain that occurs when the stomach is empty or that awakens
the patient at night. The determination of whether a patient
was suspected of having peptic ulcer disease was left to the
discretion of the participating primary care providers. Thus,
patients were included in the study based on the working
diagnosis of the primary care provider, and not based on
symptom questionnaires, tests, or other standardized instru-
ments. This was consistent with our objective to study
practice patterns and patient outcomes for patients suspected
of having peptic ulcer disease by their primary care provid-
ers. Data on patients’ symptoms at presentation were col-
lected as described below.
Participating providers identified eligible patients by fill-
ing out a brief encounter form at the time of the patient visit.
Patients were then contacted by the investigators by tele-
phone and were invited to accept further information on the
study by mail. For each patient who agreed to enroll in the
study, the index date was defined as the day the that en-
counter form was filled out.
Clinical Data Collection
For 1 yr from the index date, testing logs at the TTI centers
and electronic medical records for all centers were searched
prospectively to determine patients’ age, sex, presenting
symptoms, H. pylori testing and results, use of H. pylori
eradication therapy, use of prokinetics and antisecretory
medications (histamine-2 receptor antagonists and proton
pump inhibitors), primary care provider visits and whether
these were for persistent GI symptoms, gastroenterology
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referrals, upper GI endoscopy or radiography rates, and
additional studies or referrals.
One year after enrollment, patients were contacted by
phone to answer a brief questionnaire. The interviewer was
not aware of which primary care center the patient had
visited. Patients were asked the questions listed in Table 1.
Economic Data Collection
For patients belonging to the university-based health main-
tenance organization, financial databases were searched to
determine medical expenditures for each patient’s 1-yr
study period. These databases include all paid claims for
members’ medical services and medications. The details of
this search were the same as described in a previous study
(16).
Data Analysis
Data were entered into Excel (Microsoft, Redmond, WA)
and analyzed in Stata (Stata, College Station, TX) to yield
summary statistics as means, proportions, or (for expendi-
tures) medians and interquartile ranges. For both continuous
and ordinal measures, results were compared between TTI
and UCC centers using ordinal and log-linear regression
(19) with variances corrected for clustering of subjects
within centers (20). These methods account for the fact that
randomization did not take place at the level of the individ-
ual patient, but that the intervention was delivered at the
level of the clinical centers. Relative risks (RR) are pre-




The TTI centers identified 68 eligible patients, and 54 (79%)
agreed to participate. UCC centers identified 47 patients,
and 39 (85%) agreed to participate. No significant differ-
ences in age, sex, or symptoms at presentation were found
between groups (Table 2).
Primary Aim: Testing and Treatment for H. pylori
Table 3 shows the proportion of patients tested for H. pylori,
the results, and treatment for H. pylori in both study groups.
Table 1. Answers to Questionnaire at 1 Yr After Study Entry
Test-and-Treat
Intervention Usual Care Control p*
Respondents 48/54 (89%) 38/39 (97%)
At present, how are your stomach symptoms compared to a year ago? 0.51
Much better 22 (46%) 18 (47%)
Better 16 (33%) 9 (24%)
Same 9 (19%) 9 (24%)
Worse 1 (2%) 2 (5%)
Much worse 0 (0%) 0 (0%)
How often do you have these symptoms now? 0.15
Daily 5 (10%) 7 (18%)
Over twice a wk 10 (21%) 11 (29%)
A few times a mo 20 (41%) 13 (34%)
Never 13 (27%) 7 (18%)
How often do you take prescription medication for your symptoms? 0.004
Daily 15 (31%) 5 (13%)
Over twice a wk 0 (0%) 7 (18%)
A few times a mo 7 (15%) 8 (21%)
Never 26 (54%) 18 (47%)
How often do you take over-the-counter medication for your symptoms? 0.02
Daily 0 (0%) 6 (16%)
Over twice a wk 8 (17%) 3 (8%)
A few times a mo 13 (27%) 12 (32%)
Never 27 (56%) 17 (45%)
In the last year, how often did you miss work due to your symptoms? 0.52
Once a wk 5 (10%) 3 (8%)
Once a mo 2 (4%) 2 (5%)
Once in 3 mo 3 (6%) 4 (11%)
Once in 6 mo 3 (6%) 5 (13%)
Never 35 (73%) 24 (63%)
How would you rate the medical care you received for these symptoms by your general doctor? 0.32
Excellent 19 (40%) 11 (29%)
Very good 9 (19%) 14 (37%)
Good 13 (27%) 7 (18%)
Fair 3 (6%) 4 (11%)
Poor 4 (8%) 2 (5%)
* For overall distribution of answers to each question.
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In TTI centers, 81% of patients were tested for H. pylori, a
significantly larger proportion than the 49% tested at UCC
centers (all by laboratory serology) (p  0.004). Patients
tested at TTI centers were less likely to be H. pylori-positive
than patients at UCC centers (43% vs 58%), but the differ-
ence was not statistically significant (p  0.26). As shown
in Table 3, H. pylori treatment patterns did not differ be-
tween TTI and UCC centers: nearly all H. pylori-positive
patients and no H. pylori-negative patients were treated.
Overall, eradication regimens did not differ significantly
between TTI and UCC centers (p  0.08).
Secondary Aim: Clinical Outcomes Based on Medical
Record Review
MEDICATION. As shown in Figure 1, patients from TTI
centers tended to receive fewer prescriptions for antisecre-
tory medications than those from UCC centers. Patients
from TTI centers were significantly less likely than patients
from UCC centers to receive any proton pump inhibitor
prescriptions (26 of 54 [48%] vs 27 of 39 [69%], RR  0.70
[0.49–0.98], p  0.04), to receive repeat histamine-2 re-
ceptor antagonist prescriptions (seven of 54 [13%] vs 13 of
39 [33%], RR  0.39 [0.17–0.88], p  0.02), or to receive
either repeat histamine-2 receptor antagonist or proton
pump inhibitor prescriptions (19 of 54 [35%] vs 26 of 39
[66%], RR  0.53 [0.35–0.81], p  0.003). Patients from
TTI centers were as likely as patients from UCC centers to
receive repeat proton pump inhibitor prescriptions (13 of 54
[24%] vs 15 of 39 [39%], RR  0.63 [0.34–1.16], p 
0.14), and to receive any histamine-2 receptor antagonist
prescriptions (32 of 54 [59%] vs 21 of 39 [54%], RR  1.10
[0.76–1.59], p  0.61). Only three patients from TTI cen-
ters and two patients from UCC centers received a prescrip-
tion for a prokinetic agent (6% vs 5%, p  0.93).
PHYSICIAN VISITS. As shown in Figure 1, patients from
TTI centers were as likely as patients from UCC centers to
be referred to a gastroenterologist (13 of 54 [24%] vs 13 of
39 [33%], RR  0.72 [0.38–1.38], p  0.33). The number
of primary care visits per patient (mean  SD) subsequent
to the index visit did not differ between TTI and UCC
patients (3.1  2.8 vs 3.1  2.6, p  0.92), and neither did
subsequent primary care visits for GI symptoms (0.7  1.0
vs 0.6  0.7, p  0.78).
ENDOSCOPY, RADIOGRAPHY AND OTHER INTER-
VENTIONS. As shown in Figure 1, patients from TTI
centers were as likely as patients from UCC centers to
undergo endoscopy or upper GI contrast radiography (16 of
54 [30%] vs 12 of 39 [31%], RR  0.96 [0.52–1.80], p 
0.91). In those patients who underwent endoscopic or con-








Patients, n 54 39
Age, yr (mean  SD) 40  13 43  15 0.33
Female, n (%) 33 (61%) 25 (64%) 0.77
Presenting symptoms, n (%)
Abdominal pain 51 (94%) 32 (82%) 0.09
Nausea 10 (19%) 6 (15%) 0.69
Heartburn 1 (2%) 3 (8%) 0.21
Chest pain 4 (7%) 3 (8%) 0.96







Tested for H. pylori 44/54 (81%) 19/39 (49%) 0.004
H. pylori-positive 19/44 (43%) 11/19 (58%) 0.26
Treated for H. pylori
H. pylori-positive 17/19 (90%) 10/11 (91%)
H. pylori-negative 0/25 (0%) 0/8 (0%)
Not tested for H. pylori 0/10 (0%) 1/20 (5%)
H. pylori regimens in
H. pylori-positive
patients*
PPI  2 antibiotics 9/17 (53%) 8/10 (80%)
PPI  1 antibiotic 7/17 (41%) 1/10 (10%)
BMT 1/17 (6%) 0/10 (0%)
Unknown 0/17 (0%) 1/10 (10%)
BMT  bismuth, metronidazole, tetracycline; PPI  proton pump inhibitor.
* Overall distribution of regimens did not differ between groups (p  0.08).
Figure 1. Antisecretory medication use and subspecialty services.
Patients from test-and-treat intervention (TTI) centers were less
likely to receive any prescription for a proton pump inhibitor (Any
PPI), repeat histamine-2 receptor antagonist prescriptions (Repeat
H2RA), or repeat antisecretory medication prescriptions (Repeat
H2RA or PPI). Patients from test-and-treat intervention centers
were as likely as patients from usual care control (UCC) centers to
receive any prescription for a histamine-2 receptor antagonist (Any
H2RA) and repeat proton pump inhibitor prescriptions (Repeat
PPI), to be referred to a gastroenterologist (GI Referral), and to
undergo endoscopy or upper GI contrast radiography (esophago-
gastroduodenoscopy [EGD] or upper GI [UGI]).
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trast radiographic investigation, endoscopy was used most
often (15 of 16 in TTI and eight of 12 in UCC patients), and
there was no difference in the distribution of findings be-
tween groups (p  0.51) (Table 4).
Abdominal ultrasound was obtained in 10 TTI and five
UCC patients (p  0.47) and cholecystectomy was per-
formed in three patients from each group (p  0.68).
Secondary Aim: Clinical Outcomes Based on Patient
Questionnaire at 1 Yr
The questionnaire was answered at 1 yr by 48 of 54 (89%)
of TTI patients, and 38 of 39 (97%) of UCC patients (Table
1). Improvement in symptoms (“better” or “much better” )
was reported by 79% of patients in TTI centers and 71% of
patients in UCC centers (RR  1.11 [0.87–1.43], p  0.40),
whereas frequent (“daily” or “over twice a week” ) symp-
toms were reported by 31% and 47% of patients from these
centers, respectively, (RR  0.66 [0.39–1.43], p  0.13).
Frequent use of prescription medications was reported by
31% of patients in TTI centers and 32% of patients in UCC
centers (RR  0.99 [0.53–1.86], p  0.97), whereas fre-
quent use of over-the-counter medications was reported by
17% and 24% of patients, respectively, (RR  0.70 [0.30–
1.65], p  0.42). Missed work because of symptoms was
reported by 27% of patients in TTI centers and 37% of
patients in UCC centers (RR  0.74 [0.39–1.37], p  0.33).
Quality of care was rated as “very good” or “excellent” by
58% of patients in TTI centers and 66% of patients in UCC
centers (RR  0.89 [0.64–1.23], p  0.48).
Secondary Aim: Economic Outcomes
Economic data were available for the patients who were
members of the university-based health maintenance orga-
nization: 38 of 54 (70%) TTI patients, and 16 of 39 (41%)
UCC patients. This subpopulation tended to be younger than
the entire study population (age 37  10 yr vs 46  17 yr,
p  0.004). However, within this subpopulation, the age,
sex distribution, symptoms, primary care visits, gastroen-
terology referral rate, and endoscopy or radiography rates
were similar between TTI and UCC centers (as in the entire
study population), and rates of H. pylori testing reflected the
results in the entire study population (data not shown).
Median (interquartile range) total disease-related expen-
ditures per patient were $454 ($162–932) for TTI patients
and $576 ($327–1435) for UCC patients (p  0.17). The
mean ( SD) endoscopy-related expenditure for those who
underwent endoscopy was $703  $328 for TTI patients
and $649  $410 for UCC patients.
DISCUSSION
In this prospective study, the combination of an educational
session led by gastroenterology subspecialists and the avail-
ability of office-based serological testing for H. pylori was
associated with an increase in the use of the H. pylori
test-and-treat strategy in primary care patients with sus-
pected peptic ulcer disease when compared to passive dis-
semination of a practice guideline. Increased use of the
test-and-treat strategy was not associated with significantly
lower gastroenterology referral rates, endoscopy or upper GI
radiography rates, primary care visit rates, and disease-
related expenditures, or with significant improvements in
patients’ self-assessed clinical status, satisfaction with care,
and medication use at 1 yr.
We did not randomize patients to specific management
strategies; rather, we investigated the impact of an interven-
tion designed to increase use of the test-and-treat strategy
for suspected peptic ulcer disease. Our primary question
was: what is the effect of such an intervention on the
practice of primary care providers? Our secondary question
was: what are the clinical and economic outcomes of pa-
tients with suspected peptic ulcer disease when they are
managed with the test-and-treat strategy compared to “usual
care”? In particular, we wished to examine the test-and-treat
strategy outside the context of a strict research protocol to
reflect clinical practice in the community in the US.
Our primary finding that practitioners were indeed more
likely to pursue testing for H. pylori in centers that received
the combined intervention compared to centers that did not
is consistent with previous research on interventions de-
signed to affect practice patterns (15). Educational outreach
visits and combinations of two or more interventions have
been shown to affect the practice of clinicians, whereas
passive dissemination of information generally proves inef-
fective (15). Given our study design, we cannot determine
how much of the combined intervention’s impact can be
attributed to the on-site test or to the outreach session, and
we cannot determine the impact of passive guideline dis-
semination alone compared to no intervention at all.
Regarding our secondary aim, intermediate-term clinical
and economic outcomes for TTI center patients were not
significantly different from those of UCC center patients,
although trends were noted toward improved symptomatic
status at 1 yr and decreased resource use and cost in TTI
compared to UCC patients. In interpreting these findings,
several limitations of our study must be noted.
First, a relatively large number of patients in the UCC
centers and not all patients in TTI centers underwent H.
pylori testing and treatment. Therefore, any difference in
outcomes between the “ ideal” test-and-treat strategy and a
“usual care” control strategy could have been diluted. Sec-






Number (% of total) finding* 16/54 (30%) 12/39 (31%)
Normal 9/16 (56%) 6/12 (50%)
Esophagitis 3/16 (19%) 1/12 (8%)
Gastric ulcer 1/16 (6%) 0
Duodenal ulcer 0 2/12 (17%)
Gastric or duodenal erosions 3/16 (19%) 3/12 (25%)
* Overall distribution of findings did not differ between groups (p  0.51).
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ond, this is a small study with limited power to detect
differences in patient outcomes. For instance, the power to
detect a difference between gastroenterology referral rates
of 24% in TTI centers and 33% in UCC centers at   0.05
is only 0.16 with our sample size; a much larger study would
be needed to identify such a difference as statistically sig-
nificant (393 subjects/group for power of 0.8 and   0.05).
Third, no formal testing at entry or at follow-up (e.g.,
endoscopy, confirmation of H. pylori eradication) was per-
formed, and therefore parameters such as the actual peptic
ulcer prevalence and the success rate of H. pylori eradica-
tion are unknown in our study population. Eradication rates
of 70–87% have been reported in community practice in the
US (21), but it is unclear whether these results can be
extrapolated to our study. Some of the patients in our study
who continued to use antisecretory medication may have
had persistent peptic ulcer disease because of unsuccessful
H. pylori treatment, but it is important to note that approx-
imately one half of patients with peptic ulcer disease report
regular use of prescription medication to treat upper GI
symptoms 1 yr after successful eradication of H. pylori
infection (22).
Fourth, the relatively poor specificity of the serology test
that we studied (17, 18) could have influenced the results,
particularly if the population tested actually had a low
prevalence of H. pylori infection. More specific testing with
urea breath testing or stool antigen to detect active H. pylori
infection, which should be distinguished from false positive
serology as well as true positive serology in the absence of
active infection, may have reduced significantly any inap-
propriate use of antimicrobial therapy (23).
Finally, patients were included in this study on the basis
of the treating clinician’s suspicion of peptic ulcer disease
and not a more complex, standardized set of inclusion cri-
teria, and patient interviews at 1 yr did not use validated
instruments. Nonetheless, a valuable aspect of our study is
that it reflects clinical practice and not a strict protocol that
might be difficult to apply in the clinical setting, and the
patient questionnaires provide valuable information on clin-
ical status and satisfaction at 1 yr.
Thus, our results suggest that we may be able to increase
acceptance of a test-and-treat strategy in primary care with
education and near-patient testing, but should we aim to do
this? Numerous practice guidelines have recommended a
test-and-treat strategy in uninvestigated dyspepsia (3–7).
Recent European randomized trials have reported similar
clinical outcomes, reduced endoscopy rates, and lower ex-
penditures for the test-and-treat strategy compared to
prompt endoscopy (12, 13, 24–26). Preliminary results from
another study suggest that symptom improvement and over-
all costs are comparable with the test-and-treat strategy, a
“ test-and-endoscope” strategy, empiric proton pump inhib-
itor therapy, and prompt endoscopy (27). Therefore, current
evidence suggests that the various strategies achieve com-
parable intermediate-term clinical outcomes, and that the
test-and-treat strategy reduces endoscopy rates and may
decrease expenditures compared to prompt endoscopy.
At present, few data are available to support the effec-
tiveness of initial endoscopy in the evaluation of dyspepsia
(28). Given that intermediate term clinical outcomes seem to
be comparable with the various possible management strat-
egies (12, 13, 24–26, 29) and that test-and-treat may be less
costly than prompt endoscopy, a noninvasive initial ap-
proach may remain the first choice in primary care settings,
based on cost considerations. However, this approach ig-
nores factors such as patient satisfaction and reassurance.
Studies suggest that patient satisfaction may be greatest with
prompt endoscopy (12, 27). A normal endoscopy may pro-
vide valuable reassurance to patients, and there is evidence
that a normal endoscopy improves patients’ quality of life in
the short term (30). Notably, although most patients with
suspected peptic ulcer may be interested in establishing a
firm diagnosis, they are willing to pay relatively little for
such information (median of less than $50) (31). Finally, it
remains to be determined how many patients who are man-
aged noninvasively avoid endoscopy altogether in the long
term.
Although it is not clear whether the test-and-treat ap-
proach has advantages over other noninvasive strategies in
the shorter term (32), it is unknown whether the TTI in our
study could yield longer term benefits over UCC that may
not be apparent at 1 yr. In addition to cure in patients with
active H. pylori–related peptic ulcer disease, H. pylori erad-
ication has the potential to prevent future peptic ulcer (33–
36) and the potential (albeit unproven) to reduce the inci-
dence of gastric malignancy (37–39), and it may cure
symptoms in one of 15 patients with functional dyspepsia
(40).
In conclusion, the combination of an educational session
led by gastroenterology subspecialists and the availability of
office-based H. pylori testing may increase acceptance of
the H. pylori test-and-treat strategy by primary care provid-
ers. Further studies are necessary to determine whether
increased acceptance of the test-and-treat strategy achieves
significant improvements in intermediate term patient out-
comes or disease-related expenditures compared to “usual
care.” It remains to be established whether, by eliminating a
risk factor for several chronic diseases, the test-and-treat
strategy yields benefits in the long term that are not evident
in the intermediate term.
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